GB2470001A - Use of gamma linolenic acid in the treatment and diagnosis of cancer - Google Patents
Use of gamma linolenic acid in the treatment and diagnosis of cancer Download PDFInfo
- Publication number
- GB2470001A GB2470001A GB0907571A GB0907571A GB2470001A GB 2470001 A GB2470001 A GB 2470001A GB 0907571 A GB0907571 A GB 0907571A GB 0907571 A GB0907571 A GB 0907571A GB 2470001 A GB2470001 A GB 2470001A
- Authority
- GB
- United Kingdom
- Prior art keywords
- cancer
- many
- linolenic acid
- gla
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 27
- 201000011510 cancer Diseases 0.000 title claims abstract description 26
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 235000020664 gamma-linolenic acid Nutrition 0.000 title claims abstract description 14
- 229960002733 gamolenic acid Drugs 0.000 title claims abstract description 14
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims abstract description 10
- 238000003745 diagnosis Methods 0.000 title claims 3
- 238000000034 method Methods 0.000 claims description 11
- 210000000056 organ Anatomy 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 6
- 238000009206 nuclear medicine Methods 0.000 claims description 6
- 240000004355 Borago officinalis Species 0.000 claims description 4
- 235000007689 Borago officinalis Nutrition 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000011394 anticancer treatment Methods 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims 4
- 230000003925 brain function Effects 0.000 claims 3
- 230000018109 developmental process Effects 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 206010019233 Headaches Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 206010000060 Abdominal distension Diseases 0.000 claims 1
- 241000722877 Borago Species 0.000 claims 1
- 206010006313 Breast tenderness Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010042674 Swelling Diseases 0.000 claims 1
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 208000024330 bloating Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000037180 bone health Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 230000003779 hair growth Effects 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000000700 radioactive tracer Substances 0.000 claims 1
- 230000018406 regulation of metabolic process Effects 0.000 claims 1
- 230000027272 reproductive process Effects 0.000 claims 1
- 230000008470 skin growth Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 22
- 230000000711 cancerogenic effect Effects 0.000 abstract description 5
- 231100000315 carcinogenic Toxicity 0.000 abstract description 4
- 238000003384 imaging method Methods 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 235000021324 borage oil Nutrition 0.000 abstract 1
- 241000697872 Bactria Species 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical class [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 241001497337 Euscorpius gamma Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 150000001495 arsenic compounds Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940093920 gynecological arsenic compound Drugs 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The use of gamma linolenic acid, preferably derived from borage oil, in the treatment of cancer is disclosed. In a further embodiment, the use of radiolabelled compounds in the imaging of cancer progression is provided. The radiolabelled compounds may include gamma linolenic acid, and inorganic and organic carcinogenic and cancer treatment compounds, and may be administered by injection, orally or by inhalation. The radiolabelled compounds may then be detected using a gamma camera.
Description
The reason of all cancer types.
According to our anticancer treatment results (gamma Linolenic acid) which was extracted from medidnal herb (Borago officinalis L. (Borage)) in 2003, and also according to the chemical properties of organic and inorganic carcinogenic compounds, some specU1c relating studies, and some other indications, the reason of all cancer types may be a mistake in the human brain system. Therefore, for confirming these results, and to know which part of the brain that this mistake occurs and why? Depending on the brain anatomy science, this may finally lead to find a successful treatment for all cancer types. For this purpose, it can be used different procedure types but all of them should follow same basics and principles. These principles are; to prepare three or more different compounds; gamma Linolenic add, organic and inorganic carcinogenic and cancer treatment compounds also They should be prepared from spedfic Radioisotopes metals or they should contain spedfic Radioisotopes metals in them chemical structure. After that, these compounds will inject, inhalant or orally taken into experimental animal or human body make it possible to follow them inside this body depending on nuclear medicine imaging systems (i.e. gamma camera). This process will give us the information about the pathways of these compounds through the body tissues (them work inside the body). to confirm our study about the relation between these compounds and the brain. Our thought is when know the reason of all cancer types, them successful treatment will be possible to prepare.
In general, when above process results indicate that the preparing compounds will accumulate in a specific part or organ of the body (animal or human) more than the other parts or organs. This means this part or organ is responsible for cancer.
Moreover, after study, the anatomy information of this organ it can be known the reason of cancer which is a mistake in this part or organ.
There is another experimental process useful for knowing the reason of cancer, which is by using certain Bactria or viruses known as potential carcinogen species such as human Papilloma Virus or Helicobacter pylon Bactria.This procedure starting by preparing specific gene or protein contains isotope metals and injects it into the Bactria or viruses. After that, these species will be injected or orally take into experimental animal body for following them by one of nuclear medicine imaging systems (gamma camera) to know the action of these species by causing cancer. In this procedure, it can be used isotopes of amino acids or isotopes of nitrogen bases for preparing specific isotope for either gene or protein. Nevertheless, according to our study, using of chemical compounds is more accurate and suitable than using of Bactria or viruses.
To understand our experimental study the following example will clarify it. Firstly, preparing five compounds: the first one is gamma Linolenic acid which is contain 1C, 150 3N, 35C1, 18F, 79Br, 123j or 2H metal isotope(s) in its chemical structure. For preparing this compound, it can be used addition reaction by adding SO, 3N, 18F, 35C1 (or36Cl) , 79Br (or 81Br), 123j (or 124j) or 2H to one of the three gamma Linolenic acid double bonds.
However, if this process will change the action of this compound inside the body. Then it can be used another reaction which is substitution reaction by replacing the hydroxyl or carboxylate moiety by known moiety contain one or more from active isotopes such as, 15 3N, 35C1. However, the other four compounds, two of them are using for the treatment of cancer and the other two are carcinogenic compounds (they cause cancer). In addition, two of these compounds are inorganic and the other two are organic. Therefore, the four compounds are; for cancer treatment: Platinum metal compounds (Cis-platin) as inorganic compound and Altretamine drug as organic compound.
And the other two for cancer causes are; Arsenic compounds as inorganic compound and 1,3-Butadiene as organic compound. It can be prepared these four compounds from radioisotopes such as (192Pt, 195Pt) or any other active platinum isotopes, (73As 75As), or (11C, 15 13N, 18F) for the organic compounds.
Secondly, the five preparing compounds can be given by injection, inhalation or orally into animal body to follow them inside the body by using gamma camera as nuclear medicine images technique. This process results will make us able to know the pathways and action that these compounds will take to, treat or cause cancer.
Claims (8)
- Claims: 1. According to our study of using gamma Linolenic acid as anticancer treatment which was for five years (2003-2008) and on different cancer types, and our results that indicated that this add is a good treatment for many cancer types alone or with certain anticancer drugs such as Cis-platin.This study also used a special dosage 10 ml of our preparing solution that may contain about 0.1-0.2ml of GLA every 3 hours (8 times in the day); finally, GLA (gamma Linolenic acid) extracted from (Borago officinalis L. (Borage)) flower.
- 2. During many centuries, Borago oil has used for different purposes inside the body. It is essential for normal brain function, growth and development, bone health, stimulation of skin and hair growth, regulation of metabolism, and maintenance of reproductive processes, and it has good reputation for relieving symptoms of gout, rheumatism, and headaches. Moreover, it is wide popular for the women of PMS symptoms, this when using it as breast tenderness and feelings of depression as weH as irritability and swelling and bloating from fluid retention. However, there are many other benefits for Using of GLA by human such as it used as anticancer agent for some cancer types.
- 3. According to daim (I) and (2), the GLA (gamma Linolenic acid) is a good treatment for cancer and it is essential for normal brain function, growth and development, feelings of depression, and headaches. This mean there is an obvious relation between the brain function, GLA, and all cancer types.
- 4. Depending on recent studies, the Human brain is responsibe for ceHs growth and ceUs development, and cancer in simpe deflnition is another type of human cefls growth1 it is unsystematic cefls growth.
- 5. Many studies indicate that there is strong evidence about the relationship between the human brain and cancer, and one of these studies is Metzler studies (1978-1985) in Germany and Reiche E. M. et at (2004) study.
- 6. Nuclear medicine is widely used over the wor'd and many studies are achieved about using of nuclear medicine to treat or diagnose many diseases.
- 7. Nuclear medicine is a branch of medicine that uses radiation to provide information about the functioning of a persons specific organs or to treat disease. In most cases, physicians to make a quick, accurate diagnosis of the patient's iUness use this information, The thyroid, bones, heart, Uver and many other organs can easily image, and disorders in their function revealed. In some cases, radiation can used to treat diseased organs1 or tumours. Five Nobel Laureates have been intiniately involved wfth the use of radioactive tracers in medidne. Over 10,000 hospitals, worldwide use radioisotopes in medicine, and about 90% of the procedures are for diagnosis.
- 8. Depending on claim (7), our study by using gamma camera as nudear medicine images technique and appropriate isotopes, for finding the reason of aH cancer types, is experimentally useful.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0907571A GB2470001A (en) | 2009-05-05 | 2009-05-05 | Use of gamma linolenic acid in the treatment and diagnosis of cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0907571A GB2470001A (en) | 2009-05-05 | 2009-05-05 | Use of gamma linolenic acid in the treatment and diagnosis of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB0907571D0 GB0907571D0 (en) | 2009-06-10 |
| GB2470001A true GB2470001A (en) | 2010-11-10 |
| GB2470001A9 GB2470001A9 (en) | 2010-12-22 |
Family
ID=40792150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0907571A Withdrawn GB2470001A (en) | 2009-05-05 | 2009-05-05 | Use of gamma linolenic acid in the treatment and diagnosis of cancer |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2470001A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0037175A1 (en) * | 1980-03-14 | 1981-10-07 | Efamol Limited | Pharmaceutical compositions |
| EP0175486A1 (en) * | 1984-08-20 | 1986-03-26 | BRITISH TELECOMMUNICATIONS public limited company | Microlens manufacture |
| EP0400547A1 (en) * | 1989-06-02 | 1990-12-05 | Abbott Laboratories | Parenteral nutrition product |
| US20020188024A1 (en) * | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
| WO2005115472A2 (en) * | 2004-04-29 | 2005-12-08 | Abbott Laboratories | Compositions comprising gamma-linolenic acid and iodine for improving breast health in women |
| WO2006054316A1 (en) * | 2004-11-16 | 2006-05-26 | Magene Life Sciences Private Limited | Method(s) of preparation, stabilization, composition, and administration of gamma-linolenic acid for brain tumors |
-
2009
- 2009-05-05 GB GB0907571A patent/GB2470001A/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0037175A1 (en) * | 1980-03-14 | 1981-10-07 | Efamol Limited | Pharmaceutical compositions |
| EP0175486A1 (en) * | 1984-08-20 | 1986-03-26 | BRITISH TELECOMMUNICATIONS public limited company | Microlens manufacture |
| EP0400547A1 (en) * | 1989-06-02 | 1990-12-05 | Abbott Laboratories | Parenteral nutrition product |
| US20020188024A1 (en) * | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
| WO2005115472A2 (en) * | 2004-04-29 | 2005-12-08 | Abbott Laboratories | Compositions comprising gamma-linolenic acid and iodine for improving breast health in women |
| WO2006054316A1 (en) * | 2004-11-16 | 2006-05-26 | Magene Life Sciences Private Limited | Method(s) of preparation, stabilization, composition, and administration of gamma-linolenic acid for brain tumors |
Non-Patent Citations (2)
| Title |
|---|
| Cancer Epidemiol Biomark Prevent; Vol 2, pp 157-158 (1993). Gonz¾lez et al. "Borage consumption as a possible gastric cancer protective factor" * |
| J Pharmacy Pharmacol; Vol 56, pp 1357-1364 (2004). Ho et al. "In vitro transcutaneous delivery of tamoxifen and gamma-linolenic acid from borage oil....." * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0907571D0 (en) | 2009-06-10 |
| GB2470001A9 (en) | 2010-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zimmerman et al. | Nuclear medicine | |
| Koba et al. | MicroPET/SPECT/CT imaging of small animal models of disease | |
| US20110123639A1 (en) | Compound for improving brain functioning and/or treatment of brain disorders | |
| Koole et al. | Preclinical safety evaluation and human dosimetry of [18 F] MK-6240, a Novel PET tracer for imaging neurofibrillary tangles | |
| Maarouf et al. | Stereotactic intracavitary brachytherapy with P-32 for cystic craniopharyngiomas in children | |
| Hatanaka et al. | The present status of boron-neutron capture therapy for tumors | |
| Shavkatovna et al. | Morphological Verification Of Malignant Neoplasm Of The Urinary System With Multiple Bone Metastases | |
| Sweeney et al. | Multimodality cranial image fusion using external markers applied via a vacuum mouthpiece and a case report | |
| Brownell et al. | Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease | |
| Rischka et al. | Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C] Me-NB1 | |
| Bourdillon et al. | First clinical use of stereotaxy in humans: the key role of x-ray localization discovered by Gaston Contremoulins | |
| GB2470001A (en) | Use of gamma linolenic acid in the treatment and diagnosis of cancer | |
| CN107198780A (en) | Radiopharmaceutical composition and preparation method thereof, application | |
| Tuleasca et al. | Jaw immobilization for Gamma Knife surgery in patients with mandibular lesions: a newly, innovative approach | |
| RU2614235C2 (en) | Osteotropic radiopharmaceuticals for pet imaging | |
| JP7529305B2 (en) | Astatine solution and method for producing same | |
| Horst et al. | Frontiers in nuclear medicine | |
| Mertz | Nuclear Imaging Enters a New Era: Combining Diagnosis and Therapy, Nuclear Medicine Has the Potential to Advance Cancer Treatment and Care | |
| Othman et al. | Future of nuclear medicine-an overview | |
| Sabr et al. | STUDY THE TREATMENT PROCEDURE PROSTATE CANCER AND NEUROENDOCRINE TUMOR (NET) USING RADIOACTIVE MATERIAL LU-177 | |
| Keating et al. | 53385 Visual library of surface anatomy to establish reproducible, accurate, and precise anatomic site descriptions. | |
| Xu | The human dog 2.0.: the neurobiological effects of accelerated high-frequency repetitive transcranial magnetic stimulation in dogs | |
| Yevtushenko et al. | Age features of cervical arch and height oh human renal calyces in mature and elderly ages | |
| Kitson et al. | Preface | |
| Dorovatovskiy et al. | RESEARCH AND DEVELOPMENT OF INNOVATIVE RADIOPHARMACEUTICALS BASED ON THERAPEUTIC RADIONUCLIDE 188Re |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |